1,721,561 research outputs found
Discussione e chiusura del convegno
No full textConvegno organizzato in occasione dell’Anno internazionale del bambino e dell’adolescente con diabete. Presidente: G.V. Zuccott
Safety of a virosomal adjuvanted influenza vaccine in children suffering from chronic disease
No full textChildren suffering from chronic disease are at increased risk for complications and mortality caused by influenza. Influenza can be most effectively prevented by vaccination. Although recommended for children with chronic disease, vaccination rates remain low in this population. One possible explanation is the parents' concern that the child's underlying disease may worsen or that adverse events following influenza vaccination may be more severe than in healthy children. Data demonstrating the safety of influenza vaccination in this population are therefore crucial and may help to increase future vaccination rates in children suffering from chronic disease. The present review summarises published data on safety following vaccination with a virosomal adjuvanted influenza vaccine in children suffering from chronic disease compared with healthy children. The vaccine was shown to be immunogenic and safe in four particularly vulnerable populations: children suffering from asthma, cystic fibrosis, diabetes, or HIV infection. No changes in the course of the underlying diseases were observed after vaccination
Gestione del bambino con diabete mellito di tipo 1 : studio innovativo ospedale/territorio
No full text
The virosomal adjuvanted influenza vaccine
No full textImportance of the field: The protection conferred by influenza vaccines varies for several reasons, for example the age or degree of immune depression of the recipient. All currently available seasonal influenza vaccines are safe and substantially effective in preventing influenza in healthy people. However, elderly people and patients with chronic diseases or immune system defects need a more effective vaccine to avoid serious risks from influenza and its complications. Research has been undertaken to improve the efficacy of vaccination. Recent research includes the use of new adjuvants or antigen-presenting strategies. Areas covered in this review: The virosomal adjuvanted subunit influenza vaccine has been studied in groups for whom vaccination is recommended. We describe virosomal technology, including production and mode of action, as well as the available efficacy, immunogenicity and safety data, with the aim of understanding the benefits of this vaccine's use. What the reader will gain: A review of published data on efficacy, immunogenicity and safety from sponsor- and investigator- driven studies, focusing on recent publications. Take home message: The vaccine was generally very immunogenic and safe in all investigated populations. Its ability to induce protective antibody titers has been shown to exceed that of conventional influenza vaccines in elderly people and individuals with little or no prior exposure to the viral strains
Influvac, a trivalent inactivated subunit influenza vaccine
No full textImportance of the field: Influenza represents a major sanitary and socio-economic burden and vaccination is universally considered the most effective strategy for preventing the disease and its complications. Traditional influenza vaccines have been on the market since the late 1940s, with million of doses administered annually worldwide, and demonstrated a substantial efficacy and safety. Areas covered in this review: The trivalent inactivated subunit vaccine has been available for more than 25 years and has been studied in healthy children, adults and the elderly and in people affected by underlying chronic medical conditions. We describe vaccine technology focusing on subunit vaccine production procedures and mode of action and provide updated information on efficacy and safety available data. What the reader will gain: A review of efficacy and safety data in healthy subjects and in high risk populations from major sponsor- and investigator-driven studies. Take home message: The vaccine showed a good immunogenicity and a favorable safety profile in all target groups. In the panorama of actually available influenza vaccines, trivalent inactivated subunit vaccine represents a well-established tool for preventing flu and the associated complications
- …
